drugset / Trial / NCT02675907

Evaluation of N1539 Following Bunionectomy Surgery

NCT02675907

Phase 3 Completed 201 enrolled Baudax Bio
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following unilateral bunionectomy.

Timeline

Start
2016-01
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 30 mg Intravenous

Indications

No indication recorded.